Therefore, the perioperative use of anti-VEGF drugs can reduce intraoperative blood loss, reduce the possibility of postoperative vitreous hemorrhage and anterior chamber exudation, and improve the effectiveness of vitrectomy. The gene discussed is VEGFA; the disease is vitreous hemorrhage.